Evidence map›Paper›PMID 37298108›Full record

ArticleInternational journal of molecular sciences2023

LncRNA

Junsong Zhao, Junchao Xu, Mingming Wu, Wei Wang, Miaomiao Wang, Leiyan Yang, Huayong Cai, Qiao Xu, Ceshi Chen, Peter E Lobie and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
5.0field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Junsong ZhaoDepartment of Oncology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230027, China.
Junchao XuDepartment of Oncology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230027, China.
Mingming WuDepartment of Oncology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230027, China.
Wei WangDepartment of Oncology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230027, China.
Miaomiao WangDepartment of Oncology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230027, China.
Leiyan YangDepartment of Oncology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230027, China.
Huayong CaiDepartment of Oncology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230027, China.
Qiao XuDepartment of Oncology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230027, China.
Ceshi ChenKey Laboratory of Animal Models and Human Disease Mechanisms of the Chinese Academy of Sciences and Yunnan Province, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming 650201, China.ORCID 0000-0001-6398-3516
Peter E LobieTsinghua-Berkeley Shenzhen Institute and Institute of Biopharmaceutical and Health Engineering, Tsinghua Shenzhen International Graduate School, Tsinghua University, Shenzhen 518055, China.
Tao ZhuDepartment of Oncology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230027, China.
Xinghua HanDepartment of Oncology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230027, China.
University of Science and Technology of China · CNKunming Institute of Zoology · CNShenzhen Bay Laboratory · CN

Funding

The National Natural Science Foundation of China 82173254, 81972470, 82172618, 82103531
6 · The paper itself

Abstract

Although DNA damage repair plays a critical role in cancer chemotherapy, the function of lncRNAs in this process remains largely unclear. In this study, in silico screening identified

Indexed as

Breast NeoplasmsRNA, Long NoncodingDNA DamageFemaleHumansNuclear Factor 45 ProteinPoly(ADP-ribose) Polymerase InhibitorsTumor Suppressor ProteinsUbiquitinUbiquitin-Conjugating EnzymesUbiquitin-Protein LigasesHUWE1 protein, humanILF2 protein, humanNuclear Factor 45 ProteinPoly(ADP-ribose) Polymerase InhibitorsRNA, Long NoncodingTumor Suppressor ProteinsUBE2T protein, humanUbiquitinUbiquitin-Conjugating EnzymesUbiquitin-Protein Ligasesbreast cancerDNA damage repairILF2lncRNA H19PARP inhibitors

Identifiers

PMID37298108
PMCPMC10252380
OpenAlexW4378078198

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.